This paper describes the lead optimization of a new series of potent, selective, orally bioavailable, brain-penetrant MCH-1 receptor antagonists. A major focus of the work was to achieve a selectivity profile appropriate for in vivo efficacy studies and safety.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2008.01.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!